Cost-effectiveness analysis of the subcutaneous use of Lanadelumab for prevention of recurrent attacks of hereditary angioedema in the healthcare of the Republic of Kazakhstan
Kazakh Agency for Health Technology Assessment; Karlygash Absattarova; Bakyt Sembayeva; Kazakh Agency for Health Technology Assessment